Better testing for central nervous system malignancies
Our technological advances are intended to play an essential role in informing diagnosis and guiding treatment decisions for patients
Using licensed technology based on extensive scientific research conducted at Johns Hopkins University, we developed a proprietary molecular testing platform to detect tumor-derived DNA in cerebrospinal fluid from a standard lumbar puncture. Unlike currently available alternatives like cytology, imaging scans, or brain biopsies, our proprietary testing platform offers a highly accurate, minimally invasive and patient specific molecular profile.
CSF cytology has low sensitivity and excludes genomic data. Imaging lacks specificity and molecular profiling. Brain biopsies are challenged with insufficient tissue volume, tumor heterogeneity, and patient morbidity and mortality risk.
Introducing Belay Summit™
Summit is a liquid biopsy that tests patient CSF samples, thereby circumventing the blood brain barrier. Sequencing tumor-derived DNA in CSF can detect genomic alterations commonly associated with CNS cancers and may ultimately preempt tumor biopsy in certain instances.
Our proprietary assay detects variants and chromosomal arm length alterations from tumor-derived DNA in CSF to help inform diagnosis and management of primary and secondary CNS malignancies.
Summit focuses on testing tumor-derived DNA in CSF
With our proprietary testing platform, we provide a path forward to better patient care for those with CNS tumors
The future of neurological testing
The advances we’re introducing in the detection and management of CNS cancers represent an innovative leap in treating patients. Our new product pipeline includes significant innovations that will launch in the coming months. Contact us today to ensure you’re updated on the progress of our testing portfolio.
Introducing Belay Vantage™
Vantage is an advanced approach to determining MGMT promoter methylation status and can be ordered concomitantly with Summit.
Vantage uses quantitative polymerase chain reaction to evaluate MGMT promoter methylation in cerebrospinal fluid of individuals with known or suspected central nervous system tumors. Analysis of CSF is less invasive than brain biopsy. Vantage can be ordered using the same patient specimen as Summit.